盐酸阿考替胺片人能吃吗？

Acotiamide hydrochloride tablets can be taken by humans. The trade name is Acofide, which was developed and researched by Sawari Shinyaku Co., Ltd. and was approved for marketing in Japan in June 2013. It is used to treat postprandial fullness, epigastric distension, early satiety and other symptoms caused by functional dyspepsia (FD).

What is functional dyspepsia

Functional dyspepsia (FD) refers to a group of clinical syndromes with epigastric discomfort symptoms such as epigastric pain, epigastric distension, early satiety, belching, loss of appetite, nausea, and vomiting. After examination, organic diseases such as gastrointestinal tract, liver, gallbladder, and pancreas that cause these symptoms are excluded. The symptoms are sustainable or recurring, and the symptom onset time exceeds 6 months per year. It has a high incidence rate, with a total prevalence rate of 20% in the population, about 20% to 40% in general outpatient clinics, and about 60% to 70% in digestive specialists. It seriously affects the work, study and life of patients.

What are the effects of acotiamide hydrochloride tablets?

Acotiamide not only has a good gastric motility promotion effect and enhances gastric fundus relaxation, but also improves gastric accommodation disorders, thereby significantly reducing the early sense of fullness and distension in FD patients. At present, Japan has conducted a number of clinical studies on acotiamide, such as breath test, ultrasound test and TQT test, etc., which have proved that this product can significantly improve the symptoms of FD, is highly safe, can still maintain the improvement effect after discontinuation of the drug, and is not prone to the formation of drug resistance after repeated administration.

A large number of multi-center and large-sample randomized controlled trials have confirmed the important role of acotiamide in the treatment of FD. At present, the drug has been approved in Japan. After the completion of phase I trials in the United States and Europe, phase I clinical trials in the population are being actively prepared. By then, its application prospects will also attract the world's attention.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: